PMLiVE | Pharmaceutical industry news, articles, jobs, reports, …
WEBAug 16, 2024 | Webinars. With the flu season rapidly approaching, there is a surge in influenza and vaccine-related studies. These studies often face the significant challenge of a very short recruitment window, which necessitates thorough preparation and strategic planning during the design phase. Addressing these challenges early is crucial ...
Pfizer’s Paxlovid given FDA permission to be prescribed by US ...
WEBJul 7, 2022 · The US Food and Drug Administration (FDA) has revised the Emergency Use Authorisation (EUA) for Paxlovid (nirmatrelvir and ritonavir), authorising pharmacists to prescribe the drug to eligible patients. Under the revision, state-licensed pharmacists will be able to prescribe the drug to patients testing positive for COVID-19, on the condition ...
PME - PMLiVE
WEBPharmaceutical Market Europe – October 2023. Launch excellence – adapting to data disruption; preparing for the clinical trials of the future; the impact of cell therapies on cancer treatments.
Moderna scores FDA panel backing for mRNA-based COVID-19 …
WEBDec 18, 2020 · EMA also brings forward review meeting of vaccine. Moderna – snapping at the heels of Pfizer/BioNTech – has won backing from a US Food and Drug Administration (FDA) expert panel for its mRNA-based COVID-19 vaccine.
FDA approves Pfizer/BioNTech and Moderna’s updated COVID-19 …
WEBSep 12, 2023 · The US Food and Drug Administration (FDA) has approved updated COVID-19 vaccines from Pfizer/BioNTech and Moderna to more closely target currently circulating variants.
PME - Home
WEBHow AI and digital innovations can help agencies and pharma support HCPs in the fight against COVID-19 - PME Supplement August 2020. As the realities of COVID-19 hit and lockdown restrictions came into force around the world, agencies and pharma suddenly found themselves embracing AI and digital innovations at an accelerated rate.
Sanofi/Regeneron’s Dupixent receives FDA approval for …
WEBSep 17, 2024 · Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) as an add-on maintenance treatment for adolescents with chronic rhinosinusitis with nasal polyps (CRSwNP). The regulator’s decision, which expands its previous approval of the drug in CRSwNP patients aged 18 years and older ...
Gates Medical Research Institute initiates phase 3 study of ...
WEBMar 21, 2024 · The Bill & Melinda Gates Medical Research Institute (Gates MRI) has announced the initiation of a phase 3 clinical trial to evaluate the efficacy of a new vaccine candidate to protect adolescents and adults from pulmonary tuberculosis (TB).. If effective, the M72/AS01E vaccine could be the first available to help prevent pulmonary TB and the first new TB vaccine in over a century.
AstraZeneca presents positive phase 3 results for Imfinzi ... - PMLiVE
WEBApr 18, 2023 · AstraZeneca’s (AZ) Imfinzi has shown promising results when used before and after surgery in resectable early-stage non-small cell lung cancer (NSCLC), according to new phase 3 data presented at the American Association for Cancer Research Annual Meeting. Interim results from the AEGEAN study, which is …
Pfizer, Mylan move ahead with generics merger and spin-out
WEBNov 4, 2020 · Pfizer is planning to spin-out its generic drugs business into a joint venture with Mylan, in a deal that was due to be completed in the middle of the year. Now that the FTC has formally cleared the merger, the new firm, Viatris, will become a generics giant, with Pfizer owning 57% and Mylan owning 43%. “Today’s approval represents the ...
Skip to content